Pre-emptive approach against toxoplasmosis in allogeneic haematopoietic cell transplantation. Still far away from experience in CMV

Clinical Microbiology and Infection

Volume 28, Issue 3, March 2022, Pages 319-320

Both RS-J and JMA contributed to the final version of the manuscript.

The authors declare no conflicts of interest. No external funding was received for this work.

C. Robin et al.
Toxoplasmosis as an early complication of allogeneic hematopoietic cell transplantation
Biol Blood Marrow Transplant
(2019)
F. Derouin et al.
Prevention of toxoplasmosis in transplant patients
Clin Microbiol Infect
(2008)
M. Tomblyn et al.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective
Biol Blood Marrow Transplant
(2009)
A. Conrad et al.
A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication
Clin Microbiol Infect
(2016)
A.P. Limaye
Reasons for breakthrough CMV disease in patients who receive preemptive therapy
Am J Transplant
(2012)
F. Robert-Gangneux et al.
Toxoplasmosis in transplant recipients, Europe, 2010–2014
Emerg Infect Dis
(2018)
S. Patrat-Delon et al.
Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis
J Clin Microbiol
(2010)

There are more references available in the full text version of this article.